Efficacy and safety of cTACE versus DEB‐TACE in patients with hepatocellular carcinoma: a meta‐analysis

Conflicting results of the efficacy and safety of conventional transarterial chemo‐embolization (cTACE) vs drug‐eluting bead (DEB)‐TACE have been reported. This meta‐analysis aimed to update and re‐evaluate the efficacy and safety of cTACE compared with those of DEB‐TACE in patients with hepatocellular carcinoma (HCC).

[1]  Ying-bin Liu,et al.  Doxorubicin-eluting beads versus conventional transarterialchemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis. , 2014, International journal of clinical and experimental medicine.

[2]  C. Bartolozzi,et al.  Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma , 2014, British Journal of Cancer.

[3]  Qian Zhou,et al.  Doxorubicin‐eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma , 2014, Journal of gastroenterology and hepatology.

[4]  Haiyang Xie,et al.  Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. , 2013, Hepato-gastroenterology.

[5]  Myeong Jun Song,et al.  Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. , 2012, Journal of hepatology.

[6]  G. Passalacqua,et al.  Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol. , 2012, Oncology reports.

[7]  C. Bartolozzi,et al.  Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. , 2011, Journal of vascular and interventional radiology : JVIR.

[8]  M. Forment,et al.  Quimioembolización del hepatocarcinoma: partículas cargadas frente a quimioembolización convencional , 2011 .

[9]  C. Stroszczynski,et al.  Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE) , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[10]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[11]  R. Lencioni.  Loco‐regional treatment of hepatocellular carcinoma , 2010, Hepatology.

[12]  T. Vogl,et al.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. , 2010, AJR. American journal of roentgenology.

[13]  R. Dhanasekaran,et al.  Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) , 2010, Journal of surgical oncology.

[14]  T. Vogl,et al.  Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study , 2009, CardioVascular and Interventional Radiology.

[15]  S. Altekruse,et al.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Tai,et al.  A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  J. Bruix,et al.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. , 2007, Journal of hepatology.

[18]  A. Lloyd,et al.  DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[19]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[20]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[21]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[22]  O. Cosín,et al.  [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. , 2011, Radiologia.

[23]  D. Heresbach,et al.  Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. , 1992, Cancer.